Editor's note: This story was updated September 15.
A thick cloud of political uncertainty has been covering health-care stocks. At the core of the issue: Some reform of the health-care system seems likely, but will the high cost and record federal deficits keep President Obama from getting what he wants? Will some as yet unknown national health-care plan emerge to reengineer the current system?
And the big question for investors: Given such uncertainty, does it make sense to invest in health-care stocks before the dust settles? After all, any reform will likely mean cuts in prices of drugs and other health-care products and services, which would squeeze corporate profits.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Some smart buys exist, if you pick carefully. Many of the stocks are cheap, and some companies may actually benefit under any scenario. Also, global operators who generate half or more of their revenues from overseas aren't so affected by American health-care politics. Here are six health-care stocks that are reasonable values in this murky environment.
No matter the outcome of reform, generic drugs should benefit. Whether the government, employer or consumer is doing the spending, low-cost generics have an advantage. And over the next five years, $150-billion worth of pharmaceuticals are scheduled to come off patent, which means they're fair game for makers of generic drugs.
That's all good news for Israel-based Teva Pharmaceutical (symbol TEVA), the world's largest generic-drug maker. Standard & Poor's expects Teva, which generates 96% of sales outside its home country, to compound earnings by 17% annually over the next three years. Generics' share of pills is growing nearly everywhere, including key markets such as Japan and Europe. At the September close of $50.78, Teva sells for 15 times estimated 2009 earnings of $3.33 a share.
Teva's largest competitor in generics is Sandoz, a division of Switzerland's Novartis (NVS), which is also a Big Pharma heavyweight. Novartis, which books 70% of sales outside the U.S., has a particularly productive research lab (an impressive 16% of sales are allocated to R&D) and a nicely balanced product lineup that includes vaccines, diagnostics and eye-care products, along with brand-name and generic drugs. The stock of this financially rock-solid company yields 3.6% and, at $47.80, sells for almost 14 times projected 2009 earnings of $3.54 per share.
Perhaps the most diversified company in the industry is venerable Johnson & Johnson (JNJ). With J&J, which generates half of revenues abroad, you get a first-rate business in brand-name consumer products (Band-Aid, Listerine and Tylenol, to name a few) along with the patented drugs, medical devices and other health-care products whose pricing may be affected by health-care reform. J&J is a dividend-growth champ that yields 3.2%. The company is consistent, highly profitable and, at $60.15, sells for just 13 times earnings.
We know that drug makers are already under pressure to cut costs and to expedite the discovery and development of new drugs. Two beneficiaries of this industry trend to outsource are Covance (CVD) and Charles River Laboratories (CRL). Covance, which serves drug makers such as Eli Lilly, provides the laboratory work for one-third of all drug clinical trials worldwide (40% of revenues are from abroad).
Charles River is renowned for its business of breeding rats and mice for research. It produces the best lab rodents and has a 50% global market share in the business (the Food and Drug Administration and many other regulatory agencies require animal testing of drug candidates). Charles River then competes with the likes of Covance in the toxicology stage of drug testing. The stocks of both Covance and Charles River collapsed last fall, ultimately dropping more than 60%. Both have recovered a bit with the market and seem reasonably priced. At $57.55, Covance trades for 21 times 2009 earnings; Charles River, $36.13, trades at 15 times earnings of $2.41 per share.
Finally, we know that the aging and growth of the population means more prescriptions. Sales of generic medicines at drug stores such as CVS (CVS), the industry leader, are as good as -- or better than -- those of higher-priced, brand-name pills. CVS, which dispensed 729 million prescriptions in 2008, has 7,000 stores and opens 250 to 300 new ones each year. Most of the floor space is allocated to general merchandise, such as cosmetics, film processing and candy, but about 68% of the stores' revenues come from the pharmacy. Sales should reach $97 billion this year, and, at $36.44, the stock trades for 14 times the earnings forecast of $2.60 per share.
-
Stocks Slip to Start Fed Week: Stock Market TodayWhile a rate cut is widely expected this week, uncertainty is building around the Fed's future plans for monetary policy.
-
December Fed Meeting: Live Updates and CommentaryThe December Fed meeting is one of the last key economic events of 2025, with Wall Street closely watching what Chair Powell & Co. will do about interest rates.
-
This Is Why Investors Shouldn't Romanticize BitcoinInvestors should treat bitcoin as the high-risk asset it is. A look at the data indicates a small portfolio allocation for most investors would be the safest.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.
-
If You Put $1,000 into Qualcomm Stock 20 Years Ago, Here's What You Would Have TodayQualcomm stock has been a big disappointment for truly long-term investors.
-
If You'd Put $1,000 Into Home Depot Stock 20 Years Ago, Here's What You'd Have TodayHome Depot stock has been a buy-and-hold banger for truly long-term investors.
-
What the Rich Know About Investing That You Don'tPeople like Warren Buffett become people like Warren Buffett by following basic rules and being disciplined. Here's how to accumulate real wealth.
-
If You'd Put $1,000 Into Bank of America Stock 20 Years Ago, Here's What You'd Have TodayBank of America stock has been a massive buy-and-hold bust.
-
If You'd Put $1,000 Into Oracle Stock 20 Years Ago, Here's What You'd Have TodayORCL Oracle stock has been an outstanding buy-and-hold bet for decades.
-
How to Invest for Rising Data Integrity RiskAmid a broad assault on venerable institutions, President Trump has targeted agencies responsible for data critical to markets. How should investors respond?
-
If You'd Put $1,000 Into Sherwin-Williams Stock 20 Years Ago, Here's What You'd Have TodaySherwin-Williams stock has clobbered the broader market by a wide margin for a long time.
